Federal Register Notice: FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet 12/11 from 8 a.m. to 5 p.m. at FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center (Rm. 1503), 10903 New Hampshire Ave., Silver Spring, MD. The committee will discuss the safety and efficacy of an Amylin Pharmaceuticals BLA for metreleptin for injection for treating metabolic disorders associated with lipodystrophy, including diabetes mellitus and/or hypertriglyceridemia in pediatric and adult patients with inherited or acquired lipodystrophy. Contact Karen Abraham-Burrell, 301-796-9001. To view this notice, click here.